HALO
$63.43+0.16 (+0.25%)
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluro...
Recent News
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
Halozyme Therapeutics (NASDAQ:HALO) executives highlighted the company’s royalty-driven growth outlook and expanding subcutaneous drug delivery platform during remarks at the Citizens Life Sciences Conference, pointing to strong momentum from key partnered products, new collaboration activity, and r
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness
Halozyme Therapeutics (NasdaqGS:HALO) has appointed David Ramsay as Interim Chief Financial Officer. Ramsay, a former finance leader at the company with extensive biotechnology experience, will oversee financial operations during the search for a permanent CFO. The leadership change comes at a time when the company continues to manage growth initiatives and capital allocation priorities. For investors watching Halozyme Therapeutics, the CFO transition lands against a mixed share price...
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t
Is Halozyme Therapeutics (HALO) Pricing Reflect Long Term Prospects After Recent Share Pullback
If you are wondering whether Halozyme Therapeutics at around US$69.40 is still attractively priced or starting to look expensive, you are in the right place. The share price closed at US$69.40, with returns of a 1.4% decline over 7 days, a 3.2% decline over 30 days, a 1.3% decline year to date, but 19.4% over 1 year, 59.9% over 3 years and 65.8% over 5 years, which can shape how the market is currently weighing its risks and opportunities. Recent attention on Halozyme has been influenced by...